Inspirational Brand Award by APEA | Takeda Philippines

Takeda Philippines bags Inspirational Brand Award by Asia Pacific Enterprise Awards Regional Edition 2022


Calendar
January 4, 2023

Biopharmaceutical leader Takeda Healthcare Philippines Inc. (Takeda Philippines) receives the Inspirational Brand Award by the Asia Pacific Enterprise Awards (APEA) 2022 Regional Edition for its continuous commitment to helping patients in underserved communities access the medicines they need.

Established in 2007 by the Enterprise Asia, APEA 2022 honors exemplary business leaders and enterprises across Asia, which excelled and demonstrated resilience and growth amid the COVID-19 pandemic.

One of the 25 exemplary business leaders recognized was Takeda Philippines, a patient-focused, values-based, R&D-driven global biopharmaceutical company, that has been aiding the Philippine healthcare and Filipino patients for more than 50 years. The company has been a vital catalyst in bridging the gap of access to medicine and vaccines, providing educational grants and medical training, and conducting patient assistance programs.

In early 2022, Takeda launched its “Spot Lymphoma, Stop Lymphoma” campaign which aims to raise awareness about lymphoma and improve access to treatments in the Philippines by providing free testing to patients. Likewise, the initiative heeds the call for medical stakeholders to come together and work towards a cancer-free Philippines as mandated by Republic Act 11215 otherwise known as the National Integrated Cancer Control Act (NICCA) of 2019.

Supported by various organizations from the health sector, the campaign was able to provide free cancer testing to over 60 patients, in partnership with the Philippine Cancer Society – and is currently in partnership with the PHAP Cares foundation the social responsibility arm of the Pharmaceutical and Healthcare Association of the Philippines to continue this endeavor.

The company also partnered with the Philippine Society of Pathologists where over 1,700 attendees from the society were able to participate in several webinars which focused on diagnosing lymphoma and inflammatory disease. As the company furthers its commitment to supporting healthcare workers through a multisectoral approach, it also partnered with the Health Futures Inc Foundation in training more than 6,900 oncology nurses and 5,600 endoscopy nurses on topics related to oncology, inflammatory bowel disease related to targeted and biologic approaches to treatment.

Through its Patient Assistance Program, Takeda granted financial assistance to over 500 patients in the Philippines, helping them complete their treatment for Hodgkin Lymphoma and Inflammatory Bowel Disease (IBD).

In addition, the company also extended support to expand cancer research in the Philippines by donating an initial grant of USD16,000 to Cancer Registry and Research Philippines Foundation (CARE PH).

In 2020, Takeda launched an Access to Innovative Medicines Program designed to improve access to the care and treatment of patients, utilizing a holistic, multi-sectoral approach to improving access, addressing not only barriers across the patient journey but also spearheading initiatives to strengthen the country’s healthcare system.

“We are honored to have received this award from APEA. This recognition has motivated us, even more, to continue the mission of improving and advocating for the healthcare system in the Philippines, particularly for cancer and rare diseases. We dedicate this to our partners and patients towards better health and a brighter future,” shared Loreann Villanueva, Country Manager of Takeda in the Philippines.

The company looks forward to improving access to medicines and vaccines via the introduction of other oncology drugs and a dengue vaccine in the Philippines, supporting the advocacy of patient organizations for the localization of the NICCA, and continued policy advocacy to the government for Health Technology Assessment and Formulary inclusion of innovative drugs for cancer and rare diseases.

About Takeda

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

About Takeda Philippines

Takeda Healthcare Philippines, Inc. (THPI) is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Founded in 1968, THPI aims to broaden patient access to treatment across the country through sustainable access programs enabling affordable and integrated access solutions for disease areas such as oncology, gastroenterology, rare diseases & vaccines and by strengthening the healthcare system guided by our commitment to Patients, our People and the Planet.

For more information, visit https://www.takeda.com.

Media Contacts:

Takeda Philippines

Arabella Benedito - [email protected]

COMCO Southeast Asia

Ferdinand Bondoy - [email protected]

Joyce Yu - [email protected]

Queenie Resmundo - [email protected]

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”,

“hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.